Merck confirms its interest in buying SpringWorks
Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" before an acquisition can be agreed. So far, SpringWorks – which was spun out of Pfizer in 2017 and develops drug for cancer and rare diseases – has yet to issue its own statement on the matter.
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.
BofA analyst Alec Stranahan raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $65 from $55 and keeps a Buy rating on the ...
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback